GDTC Profile
CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company dedicated to advancing innovative cell-based immunotherapies for cancer treatment. The company's research and development efforts are centered on harnessing the power of advanced cellular technologies to create novel therapeutic approaches aimed at targeting and eradicating various types of human cancers.
CytoMed Therapeutics' leading product candidate, CTM-N2D, involves the use of expanded gamma delta T cells that are engineered with natural killer group 2D (NKG2D) ligands. These ligands target chimeric antigen receptors to enhance the cytotoxic capabilities of the T cells, aiming to improve the effectiveness of anti-cancer treatments. This approach is designed to boost the immune system's ability to identify and destroy cancerous cells.
The company is also developing iPSC-gdNKT, a cutting-edge product that utilizes induced pluripotent stem cells (iPSCs) to generate gdNKT cells. These cells represent a hybrid between gamma delta T cells and natural killer (NK) cells, combining the properties of both to create a powerful therapeutic tool. Additionally, CytoMed is working on CTM-GDT, which involves expanded gamma delta T cells engineered to exploit their multiple recognition systems for targeting and treating a broad spectrum of cancers.
Incorporated in 2018 and headquartered in Singapore, CytoMed Therapeutics Limited is at the forefront of cellular immunotherapy research. The company’s innovative approach aims to address significant unmet needs in cancer treatment, leveraging advanced cell engineering techniques to develop therapies with the potential to revolutionize the way cancers are treated.
|
